BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by abundant granulocytic myeloid-derived suppressor cells (G-MDSC = CD45+/Lin-/CD33+/CD11b+/CD15+), which infiltrate tumors and suppress anti-tumor immunity. We have previously demonstrated in a murine model of PDAC that zoledronic acid (ZA) depletes G-MDSC resulting in decreased tumor growth and improved survival. We report here the results of a phase 1 clinical trial (NCT00892242) using ZA as neo-adjuvant, perioperative therapy in patients with non-metastatic, resectable pancreatic adenocarcinoma. METHODS: Eligible PDAC patients received ZA (4mg) IV 2 weeks prior to surgery. Patients then received 2 additional doses of ZA 4 weeks apart. Blood and bone marrow were obtained from patients prior to treatment with ZA and 3 months after surgery for analysis of G-MDSC by flow cytometry. RESULTS: Twenty-three patients received pre-operative ZA with at least 6 months of follow-up Only 15 PDAC patients had non-metastatic PDAC, which was amenable to resection. ZA was well tolerated, and all adverse events were grade 1 or 2. The most common adverse events were fatigue, abdominal pain/discomfort, anorexia, and arthralgia. Of resected PDAC patients treated with ZA, 1- and 2-year overall survival (OS) was 85.7% and 33.3%, respectively, with a median OS of 18 months. This group had a 1- and 2-year progression-free survival (PFS) of 26.9% and 8.9%, respectively, with a median PFS of 12 months. The prevalence of G-MDSC was unchanged in the blood and bone marrow of PDAC patients pre- and post-treatment with ZA. CONCLUSION: ZA is safe and well tolerated as neo-adjuvant, peri-operative therapy in PDAC patients. In this small study, we did not observe a difference in OS or PFS compared to historical controls. Also, there was no difference in the prevalence of G-MDSC in the blood and bone marrow of PDAC patients pre- and post-treatment with ZA.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy characterized by abundant granulocytic myeloid-derived suppressor cells (G-MDSC = CD45+/Lin-/CD33+/CD11b+/CD15+), which infiltrate tumors and suppress anti-tumor immunity. We have previously demonstrated in a murine model of PDAC that zoledronic acid (ZA) depletes G-MDSC resulting in decreased tumor growth and improved survival. We report here the results of a phase 1 clinical trial (NCT00892242) using ZA as neo-adjuvant, perioperative therapy in patients with non-metastatic, resectable pancreatic adenocarcinoma. METHODS: Eligible PDACpatients received ZA (4mg) IV 2 weeks prior to surgery. Patients then received 2 additional doses of ZA 4 weeks apart. Blood and bone marrow were obtained from patients prior to treatment with ZA and 3 months after surgery for analysis of G-MDSC by flow cytometry. RESULTS: Twenty-three patients received pre-operative ZA with at least 6 months of follow-up Only 15 PDACpatients had non-metastatic PDAC, which was amenable to resection. ZA was well tolerated, and all adverse events were grade 1 or 2. The most common adverse events were fatigue, abdominal pain/discomfort, anorexia, and arthralgia. Of resected PDACpatients treated with ZA, 1- and 2-year overall survival (OS) was 85.7% and 33.3%, respectively, with a median OS of 18 months. This group had a 1- and 2-year progression-free survival (PFS) of 26.9% and 8.9%, respectively, with a median PFS of 12 months. The prevalence of G-MDSC was unchanged in the blood and bone marrow of PDACpatients pre- and post-treatment with ZA. CONCLUSION:ZA is safe and well tolerated as neo-adjuvant, peri-operative therapy in PDACpatients. In this small study, we did not observe a difference in OS or PFS compared to historical controls. Also, there was no difference in the prevalence of G-MDSC in the blood and bone marrow of PDACpatients pre- and post-treatment with ZA.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: H Eidtmann; R de Boer; N Bundred; A Llombart-Cussac; N Davidson; P Neven; G von Minckwitz; J Miller; N Schenk; R Coleman Journal: Ann Oncol Date: 2010-05-05 Impact factor: 32.976
Authors: Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil Journal: Lancet Oncol Date: 2011-06-05 Impact factor: 41.316
Authors: Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede Journal: World J Surg Date: 2003-02-27 Impact factor: 3.352
Authors: Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin Journal: Cancer Cell Date: 2004-10 Impact factor: 31.743
Authors: Bin Zhang; Yi Zhang; Natalie A Bowerman; Andrea Schietinger; Yang-Xin Fu; David M Kranz; Donald A Rowley; Hans Schreiber Journal: Cancer Res Date: 2008-03-01 Impact factor: 12.701
Authors: Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell Journal: N Engl J Med Date: 2011-09-25 Impact factor: 91.245
Authors: Christopher Shipp; Lisa Speigl; Nicole Janssen; Alexander Martens; Graham Pawelec Journal: Cell Mol Life Sci Date: 2016-05-28 Impact factor: 9.261
Authors: Alex G Cuenca; Angela L Cuenca; Robert D Winfield; Dallas N Joiner; Lori Gentile; Matthew J Delano; Kindra M Kelly-Scumpia; Philip O Scumpia; Michael K Matheny; Philip J Scarpace; Lizette Vila; Philip A Efron; Drake M LaFace; Lyle L Moldawer Journal: J Immunol Date: 2014-05-14 Impact factor: 5.422
Authors: Ezekiel Maloney; Tanya Khokhlova; Venu G Pillarisetty; George R Schade; Elizabeth A Repasky; Yak-Nam Wang; Lorenzo Giuliani; Matteo Primavera; Joo Ha Hwang Journal: Int Rev Immunol Date: 2017-09-29 Impact factor: 5.311